Free tool
FAERS Monitor: Xospata
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211349 or its brand name (Xospata, Gilteritinib Fumarate). Reports on generic versions are filed under their own applications.
Reports
4,079
Serious
3,848
94% of reports
Hospitalization
1,367
Death reported
1,051
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use508
- acute myeloid leukaemia342
- myelosuppression312
- platelet count decreased298
- pneumonia282
- death273
- pyrexia261
- product use issue254
- febrile neutropenia252
- acute myeloid leukaemia recurrent180
- cytopenia167
- infection161
- thrombocytopenia152
- drug ineffective151
- neutropenia144
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 8 |
| 2019 | 186 |
| 2020 | 359 |
| 2021 | 578 |
| 2022 | 628 |
| 2023 | 619 |
| 2024 | 599 |
| 2025 | 645 |
| 2026 | 452 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,080 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemia recurrentSignal | 180 | 471.8 | 406.3 | 77,053 |
| acute myeloid leukaemiaSignal | 342 | 115.7 | 104.4 | 37,940 |
| cytopeniaSignal | 167 | 71.3 | 61.4 | 11,353 |
| myelosuppressionSignal | 312 | 45.0 | 40.5 | 13,301 |
| febrile neutropeniaSignal | 252 | 19.7 | 17.4 | 4,442 |
| platelet count decreasedSignal | 298 | 14.5 | 13.0 | 3,727 |
| thrombocytopeniaSignal | 152 | 7.0 | 6.0 | 781 |
| product use issueSignal | 254 | 7.0 | 6.2 | 1,304 |
| infectionSignal | 161 | 5.7 | 4.9 | 629 |
| neutropeniaSignal | 144 | 5.5 | 4.7 | 524 |
| pneumoniaSignal | 282 | 4.5 | 4.0 | 774 |
| pyrexiaSignal | 261 | 3.9 | 3.5 | 567 |
| off label useSignal | 508 | 3.0 | 2.8 | 701 |
| death | 273 | 1.6 | 1.5 | 69 |
| drug ineffective | 151 | 0.6 | 0.5 | 45 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.